Burlington, MA-based Flexion Therapeutics in mid-November announced the full commercial launch of Zilretta (triamcinolone acetonide extended-release injectable suspension), the company’s new therapy for the management of pain associated with osteoarthritis (OA) of the knee.
Zilretta, an extended-release, intra-articular corticosteroid injectable, was approved by the US Food and Drug Administration in early October, based on data from a phase 3 randomized double-blind clinical trial involving 484 patients with knee OA pain at 37 centers worldwide; some of these findings were presented in late April at the annual meeting of the Osteoarthritis Research Society International in Las Vegas, NV.
The product has been available on a limited basis since October 23. Flexion Therapeutics has hired and trained more than 100 field sales representatives, known at the company as Musculoskeletal Business Managers, who are now deployed across the country.
